RECRUITING · INTERVENTIONAL · TREATMENT study · SLE - Systemic Lupus Erythematosus · Phase 1 · Enrollment 12 · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Official title: A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Summary: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Conditions: SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis (AAV), Connective Tissue Disease-Associated Thrombocytopenia, SLE-ITP
Study type: INTERVENTIONAL
Primary purpose: TREATMENT
Phases: PHASE1
Enrollment: 12 (ESTIMATED)
Status: RECRUITING
Completion: 2029-01-18 (ESTIMATED)